New radioactive therapy targets Hard-to-Treat colorectal cancer
Disease control
Not yet recruiting
This early-stage study tests a new drug called SNA028 in 20 people with advanced colorectal cancer that has a specific marker (GPA33). The drug uses a two-step process to deliver radiation directly to cancer cells. The main goals are to check if it is safe and how the body handle…
Phase: EARLY_PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC